Semma Therapeutics Stock

semma-tx.comHealthcareFounded: 2014Funding to Date: $158MM

Developer of trans-formative therapies designed to eliminate the use of insulin injections for type 1 diabetes patients. The company's trans-formative therapies is a cell-based therapy for diabetes which traditionally requires the use of an invasive insulin pump or multiple daily insulin injections combining proprietary cells with a state-of-the-art device to provide a replacement for the missing beta cells in a diabetic patient without immunosuppression, enabling doctors to provide a functional cure for patients with diabetes.

Register for Details

For more details on financing and valuation for Semma Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Semma Therapeutics.

Register Today

Team

Management Team

Mary Fenton
Chief Financial Officer
Felicia Pagliuca Ph.D
Vice President, Cell Biology and Research & Development and Co-Founder
Jason Gaglia
Vice President, Clinical Sciences
Jeff Imbaro
Vice President, Operations and Alliances
Bastiano Sanna Ph.D
Chief Executive Officer & President
Briannan Bintz
Director of Delivery
Christopher Thanos Ph.D
Vice President, Delivery
David Lebwohl MD
Chief Medical Officer
David DiGiusto Ph.D
Chief Technical Officer
Douglas Melton Ph.D
Scientific Co-Founder and Board Observer
Walter Blattler Ph.D
Vice President, Manufacturing

Board Members

Douglas Melton Ph.D
James Scopa JD
MPM Capital
Stephen Knight MD
F-Prime Capital Partners
William Sahlman Ph.D
David Neustaedter Ph.D
Medtronic
Kevin Raidy
Cowen Group
Mitchell Finer Ph.D
MPM Capital
Daniel Auerbach
Eight Roads
Mark Fishman MD
Todd Foley
MPM Capital

Other companies like Semma Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$4.8B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM